SMS Pharma's price drop has reclassified its valuation from 'very expensive' to 'expensive', indicating a necessary adjustment. However, the company's robust fundamentals continue to justify a cautious investment consideration.

SMS Pharma's Q4 EBITDA decreased slightly, landing at ₹399 million compared to ₹413 million in the same quarter last year. Despite the decline, their earnings margin stayed steady at 16.7% for the fourth consecutive quarter.

SMS Pharmaceuticals reported a Q4 profit of INR 20.9 crore on revenues of INR 237.94 crore for FY26, recommending a dividend of INR 0.40 per share. The board also approved the relocation of its registered office and appointed a new auditor.

SMS Pharma is maintaining its upward trajectory, surpassing the Weekly Exponential Moving Average (EMA) following a breakout, indicating a strengthening momentum. The higher highs and lows, along with increased trading volume, suggest strong support from Bollinger Mid-band and align with an overall bullish trend.